ArticleFrontiers in medicine2026
A machine learning model for 90-day mortality prediction in hepatitis B virus-related acute-on-chronic liver failure: the pivotal role of CALLY index.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a life-threatening syndrome, the condition can deteriorate rapidly, and the 90-day mortality rate is high. Due to the rapid changes in the clinical course, early and accurate risk stratification is crucial for timely decision-making and resource allocation in the ICU. This study has developed and verified a machine learning framework that integrates the C-reactive protein-albumin-lymphocyte (CALLY) index to predict the 90-day mortality rate of HBV-ACLF patients. Methods: We conducted a retrospective single-center study on 471 patients with HBV-ACLF who met the 2018 Chinese liver failure diagnosis criteria and were hospitalized in the Western Theater General Hospital from 2015 to 2023. We randomly divide the constructed data set into training set ( Results: Among the evaluated algorithms, the LightGBM model showed the strongest overall discriminative performance, with AUCs of 0.940 (95% CI, 0.916-0.964) in the training set, 0.825 (95% CI, 0.757-0.894) in the internal validation set, and 0.804 (95% CI, 0.669-0.939) in the external validation set. SHAP analysis identified international normalized ratio (INR) as the strongest predictor of mortality, followed by the CALLY index, log-transformed total bilirubin (TBIL), age, and creatinine. The CALLY-based model significantly improved risk stratification compared with the Model for End-Stage Liver Disease (MELD) score, as demonstrated by a continuous net reclassification index of 0.6223 and an integrated discrimination improvement of 0.0937. To facilitate clinical implementation, a user-friendly online tool was created to predict mortality rates. Conclusions: Our machine-learning framework integrating the CALLY index provides a high-precision and transparent decision-support tool for predicting 90-day mortality with HBV-ACLF patients. By quantifying the immune-nutritional-inflammatory axis, this approach may facilitate earlier risk stratification and personalized interventions, potentially improving survival in high-risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.